Double pancreatic cancer survival by 2020

World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer

Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can detect early stages of pancreatic cancer

LUND, Sweden - The days between 10 to 15 of May, 2016 were dedicated to the deadliest form of cancer, pancreatic cancer, by two major events that took place in Orlando, USA: the first World Pancreatic Cancer Coalition (WPCC) followed by the third AACR Pancreatic Cancer Special Conference. Both events represented major breakthroughs for Immunovia and IMMray™ PanCan-d as the following main areas in pancreatic cancer were emphasized:

Firstly, the largest global patient advocacy pancreatic cancer coalition was formed to provide a united front against this lethal disease. Immunovia sponsors the patient advocacy world coalition and will work closely with the members on both national and global levels.

Secondly, the main focus of pancreatic cancer care is now clearly early detection of stages I & II for improved chances of patient survival. Prof Borrebaeck’s talk presented clinical studies results covering over 2500 pancreatic cancer blood samples that show that IMMray™ PanCan-d can detect stages I, II, III and IV patients with an accuracy of 98%. The Scandinavian study that was finalized last year, was presented for the first time at this event and the data (that were initially press released in Nov 2015: link) showed that Immunovia’s test is able to detect the early stages of pancreatic cancer in blood with unprecedented accuracy of 96%. The talk received fantastic response from the conference participants and particularly from Key Opinion Leaders.

Thirdly, the high risk group of late onset diabetes after 50 years of age was strongly brought forward as an area that needs immediate and increased priority. Immunovia has commenced discussions to participate in the late onset diabetes programs underway.

To read the complete summary from the WPCC and AACR Pancreatic Cancer Special Conference in Orlando, click here (PDF). 


Laura Chirica, PhD, Immunovia, Sweden


About Us

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit


Documents & Links